Published in Cancer Res on November 17, 2011
Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res (2012) 2.09
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol (2015) 2.02
Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors. Cancer (2015) 1.42
Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. Ann Oncol (2013) 1.16
Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer (2016) 0.90
FGFR1-WNT-TGF-β signaling in prostate cancer mouse models recapitulates human reactive stroma. Cancer Res (2013) 0.89
Extra-abdominal desmoid tumors associated with familial adenomatous polyposis. Sarcoma (2012) 0.83
Targeting stem cell behavior in desmoid tumors (aggressive fibromatosis) by inhibiting hedgehog signaling. Neoplasia (2013) 0.81
Wnt signaling induces epithelial differentiation during cutaneous wound healing. Organogenesis (2015) 0.78
Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 37.55
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature (2010) 15.28
Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest (2004) 7.91
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells (2007) 5.83
Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol (1999) 4.04
High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer (2004) 3.22
The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest (2007) 3.15
Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med (2008) 2.97
Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cells (2004) 2.70
beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Natl Acad Sci U S A (2002) 2.55
Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol (2008) 2.48
Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism. Mol Cell Biol (2002) 2.44
Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant (2006) 2.29
Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. Cell Stem Cell (2011) 2.18
Fibrocytes: a unique cell population implicated in wound healing. Cell Mol Life Sci (2003) 2.15
Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene (1999) 2.10
Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc Natl Acad Sci U S A (2004) 2.09
Retinoids regulate stem cell differentiation. J Cell Physiol (2011) 1.91
Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J (2001) 1.91
Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells (2010) 1.78
The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc Natl Acad Sci U S A (2008) 1.77
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer (2002) 1.75
Mesenchymal stem cells spontaneously express neural proteins in culture and are neurogenic after transplantation. Stem Cells (2005) 1.73
Occurrence of desmoids in patients with familial adenomatous polyposis of the colon. Am J Med Genet (1987) 1.55
Desmoid fibromatosis is a clonal process. Hum Pathol (1996) 1.54
Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regen (2005) 1.52
Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors. J Surg Res (2010) 1.44
Desmoid tumors in patients with familial adenomatous polyposis. Cancer (1994) 1.44
ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood (2011) 1.43
ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther (2010) 1.38
Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev Dyn (1997) 1.30
Synergistic actions of hematopoietic and mesenchymal stem/progenitor cells in vascularizing bioengineered tissues. PLoS One (2008) 1.26
Fibroblast differentiation of bone marrow-derived cells during wound repair. FASEB J (2005) 1.14
Secreted frizzled-related protein 1 extrinsically regulates cycling activity and maintenance of hematopoietic stem cells. Cell Stem Cell (2009) 1.10
A gene expression signature that distinguishes desmoid tumours from nodular fasciitis. J Pathol (2006) 1.10
Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer (2008) 1.09
Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer (2010) 1.09
Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. Cancer Res (2010) 1.06
Invasion and MMP expression profile in desmoid tumours. Br J Cancer (2004) 0.98
TGF-beta modulates beta-Catenin stability and signaling in mesenchymal proliferations. Exp Cell Res (2007) 0.98
Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors. Cancer Res (2001) 0.97
Desmoids in familial adenomatous polyposis are monoclonal proliferations. Br J Cancer (2000) 0.96
Indomethacin promotes adipogenesis of mesenchymal stem cells through a cyclooxygenase independent mechanism. J Cell Biochem (2010) 0.95
APC mutations in FAP-associated desmoid tumours are non-random but not 'just right'. Hum Mol Genet (2006) 0.92
Isolation and characterization of multipotent human keloid-derived mesenchymal-like stem cells. Stem Cells Dev (2008) 0.92
Engineering strategies to emulate the stem cell niche. Trends Biotechnol (2009) 0.85
Human mesenchymal stem cells may be involved in keloid pathogenesis. Int J Dermatol (2008) 0.84
Cytokines associated with the pathophysiology of aggressive fibromatosis. J Orthop Res (2000) 0.83
Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med (2009) 10.01
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol (2006) 2.66
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol (2006) 2.49
Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) (2008) 2.47
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res (2011) 2.40
Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res (2003) 2.24
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res (2004) 2.10
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther (2004) 1.71
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci U S A (2009) 1.65
C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila) (2011) 1.57
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther (2004) 1.57
Career satisfaction of women in surgery: perceptions, factors, and strategies. J Am Coll Surg (2009) 1.56
Mast cells are required in the proliferation and remodeling phases of microdeformational wound therapy. Plast Reconstr Surg (2011) 1.53
A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila) (2008) 1.53
Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors. J Surg Res (2010) 1.44
Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol (2010) 1.42
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol (2013) 1.41
Society of University Surgeons statement on surgical resident work hours and education. Surgery (2002) 1.41
Bilateral neck exploration decreases operative time compared to minimally invasive parathyroidectomy in patients with discordant imaging. World J Surg (2013) 1.38
Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem (2004) 1.35
Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol (2013) 1.27
Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int J Cancer (2004) 1.18
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res (2013) 1.18
Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res (2007) 1.17
Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas. Gastroenterology (2012) 1.15
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol (2011) 1.12
Leiomyosarcoma of the inferior vena cava: survival after aggressive management. Ann Surg Oncol (2007) 1.10
Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface. Ann Surg Oncol (2012) 1.09
Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst (2011) 1.06
Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer (2009) 1.04
Carnosol inhibits beta-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse. Cancer Res (2005) 1.04
Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk. Ann Surg (2014) 1.03
Comparison of gastric cancer survival between Caucasian and Asian patients treated in the United States: results from the Surveillance Epidemiology and End Results (SEER) database. Ann Surg Oncol (2015) 1.03
Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer. Carcinogenesis (2004) 1.01
Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol (2009) 1.00
Necroptosis is a novel mechanism of radiation-induced cell death in anaplastic thyroid and adrenocortical cancers. Surgery (2011) 0.98
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology (2009) 0.97
Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun (2009) 0.96
Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. Cancer Res (2010) 0.96
Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer (2009) 0.92
Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res (2006) 0.92
Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst (2013) 0.92
The forest and the trees: pathways and proteins as colorectal cancer biomarkers. J Clin Oncol (2009) 0.89
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell (2016) 0.87
Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res (2013) 0.86
Clinical and financial impact of hospital readmissions after colorectal resection: predictors, outcomes, and costs. Dis Colon Rectum (2014) 0.86
Hemorrhagic shock as the initial manifestation of pheochromocytoma: report of a sequential management strategy. Endocr Pract (2012) 0.85
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg (2004) 0.85
Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics (2012) 0.84
Estrogen receptor α or β loss in the colon of Min/+ mice promotes crypt expansion and impairs TGFβ and HNF3β signaling. Carcinogenesis (2013) 0.83
Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis. Cancer Prev Res (Phila) (2010) 0.83
False negative cytology in large thyroid nodules. Ann Surg Oncol (2014) 0.82
Bronchogenic cyst masquerading as an adrenal tumor: a case of mistaken identity. Endocr Pract (2012) 0.82
Radioimmunotherapy for colorectal cancer. Clin Cancer Res (2005) 0.80
Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res (2013) 0.80
Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Exp Cell Res (2006) 0.80
The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev Res (Phila) (2011) 0.79
Clostridium difficile infection after colorectal surgery: a rare but costly complication. J Gastrointest Surg (2014) 0.79
Colorectal cancer prevention studies: the importance of defining disease risk. Ann Surg Oncol (2003) 0.77
Adenomatous polyposis coli truncation alters cytoskeletal structure and microtubule stability in early intestinal tumorigenesis. J Gastrointest Surg (2002) 0.77
The potential of non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. J Surg Oncol (2003) 0.77
Examination of Racial Disparities in the Receipt of Minimally Invasive Surgery Among a National Cohort of Adult Patients Undergoing Colorectal Surgery. Dis Colon Rectum (2016) 0.77
Safety and efficacy of radiation dose delivered via iodine-125 brachytherapy mesh implantation for deep cavity sarcomas. Ann Surg Oncol (2014) 0.76
Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis. Ann Surg (2017) 0.76
VICTOR spoiled? J Clin Oncol (2010) 0.75
Reply: the effects of negative pressure on blood supply and the adipogenic role of edema. Plast Reconstr Surg (2013) 0.75
Controversies in the surgical management of GIST in the era of imatinib. Oncology (Williston Park) (2009) 0.75
Current management of metastatic gastrointestinal stromal tumor: a case report. Clin Adv Hematol Oncol (2003) 0.75
Initiation of a Transanal Total Mesorectal Excision Program at an Academic Training Program: Evaluating Patient Safety and Quality Outcomes. Dis Colon Rectum (2017) 0.75
Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern. Am J Surg Pathol (2017) 0.75
Outcomes of Abdominal Surgery in Patients With Mechanical Ventricular Assist Devices: A Multi-Institutional Study. Ann Surg (2017) 0.75
Impact of Procedural Specialty on Maternity Leave and Career Satisfaction Among Female Physicians. Ann Surg (2017) 0.75
Cutaneous Radiation-associated Breast Angiosarcoma: Radicality of Surgery Impacts Survival. Ann Surg (2017) 0.75
Surgeon Volume Correlates with Reduced Mortality and Improved Quality in the Surgical Management of Diverticulitis. J Gastrointest Surg (2016) 0.75